Advertisement

Topics

UK’s NICE invites Roche to submit CDF proposal for urothelial cancer drug

02:36 EDT 3 Aug 2017 | Pharmaceutical Business Review

The National Institute for Health and Care Excellence (NICE) has turned down Roche’s urothelial cancer drug atezolizumab citing the need for stronger evidence in clinical and cost effectiveness.

Original Article: UK’s NICE invites Roche to submit CDF proposal for urothelial cancer drug

NEXT ARTICLE

More From BioPortfolio on "UK’s NICE invites Roche to submit CDF proposal for urothelial cancer drug"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...